ATOS · Atossa Therapeutics, Inc. · Financials
$2.48
-0.03 (-1.20%)
At close · Sep 14
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a going concern.”View the 10-Q filed Aug 7, 2026
Market Cap
$25.20M
Shares
9.98M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$1758
-95.6%
FY2015
Net Income
-$34.77M
-36.3%
FY2025
Gross Margin
-7431.91%
-7531.9pp
FY2015
Operating Margin
-725746.19%
-695423.2pp
FY2015
Diluted EPS
-$4.04
-32.9%
FY2025
Operating Cash Flow
-$29.76M
-41.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1758 | — | — | — | — | — | — | — | — | — | — | $1758 | $40.14K | $632.56K | $481.84K | $1500 | — | |
| $132.41K | — | — | — | — | — | — | — | — | — | — | $132.41K | $0 | $345.52K | $35.75K | $5164 | — | |
| -$130.65K | — | — | — | — | — | — | — | — | — | — | -$130.65K | $40.14K | $137.09K | $416.21K | -$95.69K | — | |
| — | — | — | — | — | — | — | — | — | — | — | -7431.91% | 100% | 21.67% | 86.38% | -6379.33% | — | |
| $21.2M | $21.19M | $14.12M | $17.33M | $15.08M | $9.21M | $6.61M | $6.65M | $4.21M | $2.33M | $770.43K | $2.36M | $1.11M | $1.11M | $1.97M | — | — | |
| $18.05M | $15.96M | $13.5M | $14.04M | $12.61M | $11.31M | $8M | $10.62M | $7.22M | $4.86M | $6.48M | $8.85M | $8.05M | $8.56M | $3.04M | $3.17M | — | |
| — | — | — | — | — | — | $27.6K | $30.8K | $30K | $103.04K | — | — | — | — | — | — | — | |
| $11K | — | — | — | $8000 | $23K | $47K | $52.79K | $44.2K | $128.99K | $303.48K | $272.63K | $480.31K | $472.93K | $130.55K | $15.62K | — | |
| $39.25M | $37.14M | $27.62M | $31.38M | $27.69M | $20.52M | $14.61M | $17.27M | $11.43M | $7.65M | $7.97M | $12.63M | $12.21M | $10.92M | $5.49M | $3.33M | — | |
| -$39.25M | -$37.14M | -$27.62M | -$31.38M | -$27.69M | -$20.52M | -$14.61M | -$17.27M | -$11.43M | -$7.65M | -$7.97M | -$12.76M | -$12.17M | -$10.78M | -$5.07M | -$3.43M | — | |
| — | — | — | — | — | — | — | — | — | — | — | -725746.19% | -30322.96% | -1704.93% | -1052.01% | -228612.67% | — | |
| -$30.49M | — | — | — | -$27.68M | -$20.5M | -$14.56M | -$17.21M | -$11.39M | -$7.52M | -$7.67M | -$12.49M | -$11.69M | -$10.31M | -$4.94M | -$3.41M | — | |
| $16.8K | — | — | — | — | — | — | — | — | — | — | — | $15.77K | $360 | $12.04K | $17.99K | — | |
| $1.55M | $2.38M | $4.05M | $4.34M | $877K | $6000 | — | — | — | — | — | — | $260 | $295 | $1219 | $4914 | — | |
| -$6000 | -$6000 | -$223K | -$70K | -$146K | -$91K | $51K | $25.65K | $29.3K | $154 | $1.6M | $431 | $260 | — | — | — | — | |
| -$37.71M | -$34.77M | -$25.5M | -$30.09M | -$26.96M | -$20.61M | -$17.83M | -$17.24M | -$11.4M | -$8.12M | -$6.37M | -$12.76M | -$12.17M | -$10.78M | -$5.08M | -$3.44M | — | |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | $0 | $0 | $0 | $0 | $0 | — | |
| -$37.71M | -$34.77M | -$25.5M | -$30.09M | -$26.96M | -$20.61M | -$17.83M | -$17.24M | -$11.4M | -$8.12M | -$6.37M | -$15.76M | -$14.66M | -$10.78M | -$5.08M | -$3.44M | -$1.09M | |
| — | — | — | — | — | — | — | — | — | — | — | -896491.64% | -36518.83% | -1704.94% | -1054.26% | -229484.53% | — | |
| — | — | — | — | — | -$20.61M | -$22.33M | -$17.24M | -$22.88M | -$10.69M | -$6.37M | — | — | — | — | — | — | |
| USD/shares | -$4.34 | -$4.04 | -$3.04 | -$3.60 | -$3.15 | -$2.70 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$4.34 | -$4.04 | -$3.04 | -$3.60 | -$3.15 | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 8.61M | 8.39M | 8.41M | 8.44M | 7.8M | 753.9333 | 566.46K | 277.18K | 64.98K | 196.49K | 126.34K | 1.6M | 1.03M | 830.2K | 607.85K | — |
| shares | — | 8.61M | 8.39M | 8.41M | 8.44M | 7796.6667 | 753.9333 | 566.46K | 277.18K | 64.98K | 196.49K | 126.34K | 1.6M | 1.03M | 830.2K | 607.85K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2024: $1.48M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.90×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.88×
Peer medians compare against the 245 similar-size Biotechnology companies (of 516 listed).